Donepezil therapy in clinical practice: a randomized crossover study.
暂无分享,去创建一个
R. Sperling | J. Growdon | D. Schoenfeld | S. Greenberg | T. Gómez-Isla | K. Daffner | D. Hayden | D A Schoenfeld | J H Growdon | T Gomez-Isla | S M Greenberg | M. Meadows | K R Daffner | R A Sperling | M. Tennis | D L Hayden | M K Tennis | L B Brown | K L Walsh | C Corwin | P Friedman | M E Meadows | D. Hayden | K. Walsh | S. Greenberg | M. Meadows | L. Brown | C. Corwin | P. Friedman | Laura B. Brown | Claire Corwin | Katie L. Walsh | Pamela Friedman
[1] K. Davis,et al. A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.
[2] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease , 1984, Neurology.
[3] D. Drachman,et al. Human memory and the cholinergic system. A relationship to aging? , 1974, Archives of neurology.
[4] L. Schneider,et al. Eligibility of Alzheimer's Disease Clinic Patients for Clinical Trials , 1997, Journal of the American Geriatrics Society.
[5] R. Mohs,et al. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. , 1998, Archives of internal medicine.
[6] A Whitehead,et al. Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' Collaboration. , 1998, JAMA.
[7] B T Hyman,et al. Clinical and pathological correlates of apolipoprotein E ε4 in Alzheimer's disease , 1996, Annals of neurology.
[8] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.
[9] M. Roth,et al. The Association Between Quantitative Measures of Dementia and of Senile Change in the Cerebral Grey Matter of Elderly Subjects , 1968, British Journal of Psychiatry.
[10] I. Olkin,et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. , 1996, JAMA.
[11] S. Gauthier,et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[12] R. Mohs,et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease , 1998, Neurology.
[13] Rachelle S. Doody,et al. DONEPEZIL STUDY GROUP. A 24-WEEK, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL OF DONEPEZIL IN PATIENTS WITH ALZHEIMER'S DIS-EASE , 1998 .
[14] H. Soininen,et al. Tetrahydroaminoacridine improves the recency effect in Alzheimer's disease , 1998, Neuroscience.
[15] J. Poirier,et al. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease , 1998, Neurology.
[16] L. Friedhoff,et al. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial , 1996 .
[17] A D Roses,et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. , 1998, The New England journal of medicine.
[18] D. Drachman,et al. Memory and cognitive function in man , 1977, Neurology.
[19] D. P. Osborne,et al. A memory test for longitudinal measurement of mild to moderate deficits. , 1980 .
[20] Arthur L. Benton,et al. Word fluency and brain damage , 1967 .
[21] R. Bartus,et al. The cholinergic hypothesis of geriatric memory dysfunction. , 1982, Science.
[22] L. Friedhoff,et al. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group. , 1996, Dementia.